Amprius Secures $75 Million Grant for American High-Energy Density Battery Production

What happened

Amprius Technologies announced it was awarded a grant to support conversion of an existing domestic EV battery production line to manufacture high-energy density cells intended for unmanned aerial systems. The award was made through a Department of War program intended to fund domestic manufacturing capabilities deemed critical to national defense.

Sources: S1

Project scope and timeline

Amprius plans to use the funds to reconfigure an existing U.S.-based electric vehicle battery production line operated by a major South Korean manufacturer. The company states the conversion project is expected to cost approximately $100 million and that, at completion, planned for early 2028, the line is expected to have the capacity to produce 12 million Amprius cells annually. The cells are intended to meet the domestic sourcing requirements of the National Defense Authorization Act.

Sources: S1

Why this may matter (inference)

If executed as described, the retrofitted line would expand Amprius’ NDAA-compliant domestic manufacturing capacity and add to its global manufacturing network. The company frames the award as enabling larger-scale supply of high-energy pouch cells for Group 1, 2, and 3 unmanned aerial systems and as strengthening a domestic production source for defense-related battery requirements.

Sources: S1

Context and company statements

Amprius describes itself as a developer of silicon-anode lithium-ion batteries and says it employs a contract manufacturing strategy to support scalable production. The release includes forward-looking statements about the anticipated value, funding, scope and timing of the agreement and lists risks and conditions that could affect outcomes.

Sources: S1

What remains uncertain

• The press release notes that a majority of the total award amount remains unfunded and is subject to future appropriations, and that payments depend on achievement and acceptance by the U.S. Government of specified milestones.
• The announcement is an issuer press release and includes forward-looking statements; performance at commercial volume and timing are presented as expectations rather than independently verified outcomes.
• The project relies on third parties and partners for certain obligations and on the successful conversion and qualification of cells at scale; those dependencies are called out as risks by the company.